Company Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response.
The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.
It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.
In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations.
Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct.
Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2000 |
| IPO Date | Jan 31, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Cameron Durrant |
Contact Details
Address: 830 Morris Turnpike, 4th Floor Short Hills, New Jersey 07078 United States | |
| Phone | (973) 200-3100 |
Stock Details
| Ticker Symbol | HGENQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001293310 |
| CUSIP Number | 444863104 |
| ISIN Number | US4448632038 |
| Employer ID | 77-0557236 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Durrant M.D., MBA | Chairman, Chief Executive Officer, Principal Financial and Accounting Officer |
| Dr. Dale Chappell M.B.A., M.D., MBA | Chief Scientific Officer and Director |
| Robert Atwill M.B.A. | Senior Vice President and Head of Asia-Pacific Region and Business Development |
| Edward P. Jordan M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 8, 2024 | 8-K | Current Report |
| Oct 12, 2023 | 25-NSE | Filing |
| Sep 14, 2023 | 8-K | Current Report |
| Aug 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jul 25, 2023 | 8-K | Current Report |
| May 15, 2023 | 10-Q | Quarterly Report |
| Apr 25, 2023 | 10-K/A | [Amend] Annual report |
| Apr 19, 2023 | 8-K | Current Report |
| Apr 6, 2023 | 8-K | Current Report |
| Mar 30, 2023 | 10-K | Annual Report |